What is the share price of Shree Ganesh Remedies Ltd (SGRL) today?
The share price of SGRL as on 5th December 2025 is ₹445. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Shree Ganesh Remedies Ltd (SGRL) share?
The past returns of Shree Ganesh Remedies Ltd (SGRL) share are- Past 1 week: -5.04%
- Past 1 month: -8.40%
- Past 3 months: -22.09%
- Past 6 months: -28.21%
- Past 1 year: -38.94%
- Past 3 years: 67.19%
- Past 5 years: 244.12%
What are the peers or stocks similar to Shree Ganesh Remedies Ltd (SGRL)?
The peers or stocks similar to Shree Ganesh Remedies Ltd (SGRL) include:What is the market cap of Shree Ganesh Remedies Ltd (SGRL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shree Ganesh Remedies Ltd (SGRL) is ₹571.34 Cr as of 5th December 2025.What is the 52 week high and low of Shree Ganesh Remedies Ltd (SGRL) share?
The 52-week high of Shree Ganesh Remedies Ltd (SGRL) is ₹950 and the 52-week low is ₹423.What is the PE and PB ratio of Shree Ganesh Remedies Ltd (SGRL) stock?
The P/E (price-to-earnings) ratio of Shree Ganesh Remedies Ltd (SGRL) is 24.78. The P/B (price-to-book) ratio is 3.94.Which sector does Shree Ganesh Remedies Ltd (SGRL) belong to?
Shree Ganesh Remedies Ltd (SGRL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Shree Ganesh Remedies Ltd (SGRL) shares?
You can directly buy Shree Ganesh Remedies Ltd (SGRL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Shree Ganesh Remedies Ltd
SGRL Share Price
445.004.70% (-21.95)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SGRL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SGRL Performance & Key Metrics
SGRL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.99 | 3.94 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
SGRL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SGRL Company Profile
Shree Ganesh Remedies Limited is engaged in manufacturing and dispatching of drug intermediates and chemicals for pharmaceutical industry. The Company manufactures products relating to antipsychotic, antiseptic, deprotonation reactions etc.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
SGRL Sentiment Analysis
SGRL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SGRL Stock Summary · May 2025
The company is currently facing significant revenue challenges, with a notable decline attributed to pricing pressures and a slowdown in key markets, particularly Europe. Despite these hurdles, there is optimism surrounding the CRAMS segment, which is expected to contribute substantially to future revenues, driven by ongoing projects and strategic partnerships, especially in Japan. Investments in R&D and infrastructure are being prioritized to enhance production capabilities and meet evolving customer demands, while a focus on operational efficiencies has led to improved EBITDA margins. Management is cautiously optimistic about future growth, anticipating a consolidation year in FY26, yet remains committed to innovative product development and expanding market presence in both domestic and international arenas.
SGRL Stock Growth Drivers
SGRL Stock Growth Drivers
7Strategic Infrastructure Development
The company has made significant progress in enhancing its production capabilities, particularly at the Dahej
Successful Product Launches and Innovations
The company has successfully launched a 2.5 MW solar power park, which is anticipated to
SGRL Stock Challenges
SGRL Stock Challenges
6Revenue Decline
The company reported a significant revenue decline of 35% year-on-year for Q4 FY25, primarily due
EBITDA and Profitability Challenges
The EBITDA for Q4 FY25 was ₹9.88 crore, representing a 42% year-on-year decrease, with the
SGRL Forecast
SGRL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SGRL
SGRL
Income
Balance Sheet
Cash Flow
Annual Normal View
SGRL Income Statement
SGRL Income Statement
Annual Normal View
| Financial Year | FY 2024 | FY 2025 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 128.97 | 112.33 | 110.81 | |||
Raw Materials | 63.36 | 37.52 | 69.77 | |||
| Power & Fuel Cost | 6.39 | 7.89 | ||||
| Employee Cost | 8.41 | 10.12 | ||||
| Selling & Administrative Expenses | 9.42 | 11.27 | ||||
| Operating & Other expenses | -3.49 | 2.59 | ||||
EBITDA | 44.88 | 42.94 | 41.04 | |||
| Depreciation/Amortization | 6.11 | 9.57 | 10.13 | |||
| PBIT | 38.77 | 33.37 | 30.91 | |||
| Interest & Other Items | 0.61 | 2.11 | 3.31 | |||
| PBT | 38.16 | 31.26 | 27.60 | |||
| Taxes & Other Items | 10.05 | 8.20 | 7.19 | |||
| Net Income | 28.11 | 23.06 | 20.41 | |||
| EPS | 21.88 | 17.96 | 15.90 | |||
| DPS | 0.50 | 0.00 | 0.00 | |||
| Payout ratio | 0.02 | 0.00 | 0.00 |
SGRL Company Updates
SGRL Stock Peers
SGRL Past Performance & Peer Comparison
SGRL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Shree Ganesh Remedies Ltd | 24.78 | 3.94 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
SGRL Stock Price Comparison
Compare SGRL with any stock or ETFCompare SGRL with any stock or ETF
SGRL
SGRL Holdings
SGRL Shareholdings
SGRL Promoter Holdings Trend
SGRL Promoter Holdings Trend
SGRL Institutional Holdings Trend
SGRL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SGRL Shareholding Pattern
SGRL Shareholding Pattern
SGRL Shareholding History
SGRL Shareholding History
Foreign Institutions
Mutual Funds Invested in SGRL
Mutual Funds Invested in SGRL
No mutual funds holding trends are available
Top 1 Mutual Funds holding Shree Ganesh Remedies Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 120/124 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SGRL stock
smallcases containing SGRL stock
Looks like this stock is not in any smallcase yet.
SGRL Events
SGRL Events
SGRL Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SGRL Dividend Trend
No dividend trend available
SGRL Upcoming Dividends
SGRL Upcoming Dividends
No upcoming dividends are available
SGRL Past Dividends
SGRL Past Dividends
Cash Dividend
Ex DateEx DateSep 7, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 7, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹1.75
Dividend/Share
₹1.75
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 1, 2020
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 1, 2020
Cash Dividend
Ex DateEx DateAug 22, 2019
Final
Final | Div/Share: ₹1.25
Dividend/Share
₹1.25
Ex DateEx Date
Aug 22, 2019
SGRL Stock News & Opinions
SGRL Stock News & Opinions
Articles & Videos
Earnings
Shree Ganesh Remedies consolidated net profit declines 22.62% in the September 2025 quarter
Net profit of Shree Ganesh Remedies declined 22.62% to Rs 4.96 crore in the quarter ended September 2025 as against Rs 6.41 crore during the previous quarter ended September 2024. Sales declined 6.22% to Rs 30.32 crore in the quarter ended September 2025 as against Rs 32.33 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales30.3232.33 -6 OPM %31.7334.98 - PBDT9.3011.06 -16 PBT6.718.64 -22 NP4.966.41 -23 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Shree Ganesh Remedies standalone net profit declines 22.74% in the September 2025 quarter
Net profit of Shree Ganesh Remedies declined 22.74% to Rs 4.96 crore in the quarter ended September 2025 as against Rs 6.42 crore during the previous quarter ended September 2024. Sales declined 6.22% to Rs 30.32 crore in the quarter ended September 2025 as against Rs 32.33 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales30.3232.33 -6 OPM %31.7634.98 - PBDT9.3111.07 -16 PBT6.728.65 -22 NP4.966.42 -23 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Shree Ganesh Remedies to table results
Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Shree Ganesh Remedies AGM scheduled
Shree Ganesh Remedies announced that the Annual General Meeting(AGM) of the company will be held on 9 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Shree Ganesh Remedies consolidated net profit declines 25.81% in the June 2025 quarter
Net profit of Shree Ganesh Remedies declined 25.81% to Rs 3.45 crore in the quarter ended June 2025 as against Rs 4.65 crore during the previous quarter ended June 2024. Sales declined 0.44% to Rs 24.67 crore in the quarter ended June 2025 as against Rs 24.78 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales24.6724.78 0 OPM %29.5932.81 - PBDT7.028.35 -16 PBT4.606.33 -27 NP3.454.65 -26 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Shree Ganesh Remedies to convene board meeting
Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Shree Ganesh Remedies consolidated net profit declines 47.66% in the March 2025 quarter
Net profit of Shree Ganesh Remedies declined 47.66% to Rs 6.59 crore in the quarter ended March 2025 as against Rs 12.59 crore during the previous quarter ended March 2024. Sales declined 34.56% to Rs 24.43 crore in the quarter ended March 2025 as against Rs 37.33 crore during the previous quarter ended March 2024. For the full year,net profit declined 17.93% to Rs 23.07 crore in the year ended March 2025 as against Rs 28.11 crore during the previous year ended March 2024. Sales declined 13.74% to Rs 108.60 crore in the year ended March 2025 as against Rs 125.90 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales24.4337.33 -35 108.60125.90 -14 OPM %40.4045.38 -36.1033.21 - PBDT11.2018.11 -38 40.8344.27 -8 PBT8.7716.25 -46 31.2738.16 -18 NP6.5912.59 -48 23.0728.11 -18 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Shree Ganesh Remedies schedules board meeting
Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Shree Ganesh Remedies to table results
Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Shree Ganesh Remedies standalone net profit declines 1.98% in the September 2024 quarter
Net profit of Shree Ganesh Remedies declined 1.98% to Rs 6.42 crore in the quarter ended September 2024 as against Rs 6.55 crore during the previous quarter ended September 2023. Sales declined 3.26% to Rs 32.33 crore in the quarter ended September 2024 as against Rs 33.42 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.3333.42 -3 OPM %34.9827.59 - PBDT11.0710.01 11 PBT8.658.60 1 NP6.426.55 -2 Powered by Capital Market - Live
1 year agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant